X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2023/10/31/2770682/0/en/FDA-approves-Novartis-Cosentyx-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504
https://www.prnewswire.com/news-releases/fda-approves-novartis-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases-301949928.html
https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_.pdf
https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa
https://www.fiercepharma.com/pharma/next-immunology-growth-novartis-targets-atypical-areas-and-car-t-cosentyx-set-one-more-show
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-hidradenitis-suppurativa
https://www.globenewswire.com/news-release/2023/02/03/2601665/0/en/Patients-with-hidradenitis-suppurativa-experienced-sustained-efficacy-and-symptom-improvement-at-one-year-when-treated-with-Novartis-Cosentyx.html
https://pharmaphorum.com/news/abbvie-sheds-autoimmune-disease-drug-in-blow-to-partner-inventiva/
https://www.fiercepharma.com/pharma/novartis-ties-hq-raid-anticompetition-probe-cosentyx-patent-fight-against-lilly
https://www.globenewswire.com/news-release/2022/09/10/2513541/0/en/Novartis-Cosentyx-shows-clinically-meaningful-symptom-improvements-in-patients-with-hidradenitis-suppurativa-in-pivotal-Phase-III-trials.html
https://www.pharmatimes.com/news/eu_approves_norvatis_cosentyx_for_childhood_arthritis_1450588
https://www.globenewswire.com/news-release/2022/05/20/2447681/0/en/Novartis-Cosentyx-secukinumab-receives-positive-CHMP-opinion-for-expanded-use-in-childhood-arthritic-conditions.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504
https://www.prnewswire.com/news-releases/novartis-cosentyx-receives-fda-approval-for-the-treatment-of-children-and-adolescents-with-enthesitis-related-arthritis-and-psoriatic-arthritis-301450193.html
https://www.fiercebiotech.com/biotech/acelyrin-reels-250m-to-fund-three-late-stage-trials-inflammatory-disease-antibody-licensed
https://www.europeanpharmaceuticalreview.com/news/165277/cosentyxdisplays-a-72-percent-reduced-arthritis-flare-risk/
https://www.clinicaltrialsarena.com/news/novartis-cosentyx-flare-idiopathic-arthritis/
http://www.pharmafile.com/news/589029/novartis-autoinjector-effective-treating-psoriasis
https://www.biospectrumasia.com/analysis/28/19032/key-players-in-psoriasis-offer-strong-support-through-branded-digital-channels-in-australia.html
http://www.pharmafile.com/news/587067/nice-approves-secukinumab-young-people-severe-plaque-psoriasis
http://www.pharmatimes.com/news/nice_recommends_novartis_consentyx_for_children_with_psoriasis_1376182
https://endpts.com/kevin-judice-plays-dice-pivoting-from-a-60m-raise-straight-to-the-big-s-1-filing/
https://www.novartis.com/news/media-releases/novartis-secures-new-approval-china-cosentyx-secukinumab-pediatric-psoriasis
http://www.pharmatimes.com/news/novartis_cosentyx_wins_nice_backing_for_non-radiographic_axial_spondyloarthritis_1371828
https://endpts.com/novartis-stakes-another-phiii-win-for-cosentyx-goes-deeper-into-pediatric-markets/
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis
http://www.pharmatimes.com/news/cosentyx_gains_eu_approval_for_new_label_extension_1364449
https://www.clinicaltrialsarena.com/news/novartis-positive-cosentyx-trial/
https://www.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-data-reinforcing-cosentyx-first-line-systemic-treatment-pediatric-psoriasis
https://www.fiercepharma.com/marketing/singer-cyndi-lauper-launches-another-novartis-psoriasis-awareness-campaign-hosts-podcast
https://www.fiercepharma.com/pharma/abbvie-s-skyrizi-stands-to-gain-from-physicians-move-away-from-older-meds-like-amgen-s
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis
https://endpts.com/ucb-touts-another-psoriasis-win-this-time-over-cosentyx-as-they-look-to-break-into-packed-market/
https://www.healio.com/news/dermatology/20200724/bimekizumab-shows-positive-phase-3b-results-against-cosentyx#:~:text=The%20bimekizumab%20group%20was%20superior,causing%20pain%2C%20discomfort%20and%20stigma.
http://www.pharmafile.com/news/554231/ucbs-investigational-il-17a-and-il-17f-inhibitor-outclasses-novartis-cosentyx-plaque-pso
https://www.prnewswire.com/news-releases/lillys-mirikizumab-superior-to-cosentyx-secukinumab-in-a-phase-3-study-for-patients-with-moderate-to-severe-plaque-psoriasis-301095301.html
https://www.cosmopharma.com/~/media/Files/C/Cosmo-Pharmaceuticals-V2/news/press/pr2020/200626/200626_Cosmo_Pharmaceuticals_Press_Release_MB%20MMX_EN1.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504
https://www.fiercepharma.com/marketing/eli-lilly-s-taltz-beats-novartis-to-punch-fda-approval-spondyloarthritis
https://uk.reuters.com/article/us-novartis-cosentyx/novartis-wins-expanded-european-ok-for-cosentyx-amid-pursuit-of-5-billion-sales-idUKKCN22B0IP
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-new-indication-axial-spondyloarthritis-spectrum
http://www.pmlive.com/pharma_news/cosentyx,_entresto_drive_topline_growth_for_novartis_in_q4_1323659
https://www.fiercepharma.com/marketing/biologics-and-dtc-mainstream-ad-campaigns-now-price-admission-for-many-biologic-brands
https://www.fiercepharma.com/pharma/abbvie-s-skyrizi-bests-novartis-cosentyx-clearing-patients-skin-head-to-head-trial
Market Place
Share 
